52 related articles for article (PubMed ID: 30496698)
1. The unraveling of substrate specificity of histone deacetylase 6 domains using acetylome peptide microarrays and peptide libraries.
Kutil Z; Skultetyova L; Rauh D; Meleshin M; Snajdr I; Novakova Z; Mikesova J; Pavlicek J; Hadzima M; Baranova P; Havlinova B; Majer P; Schutkowski M; Barinka C
FASEB J; 2019 Mar; 33(3):4035-4045. PubMed ID: 30496698
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6.
Osko JD; Christianson DW
Biochemistry; 2019 Dec; 58(49):4912-4924. PubMed ID: 31755702
[TBL] [Abstract][Full Text] [Related]
3. HDAC6 and Ubp-M BUZ domains recognize specific C-terminal sequences of proteins.
Hard RL; Liu J; Shen J; Zhou P; Pei D
Biochemistry; 2010 Dec; 49(50):10737-46. PubMed ID: 21090589
[TBL] [Abstract][Full Text] [Related]
4. Structure, Functions and Selective Inhibitors of HDAC6.
Liang T; Fang H
Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
[TBL] [Abstract][Full Text] [Related]
5. Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome.
Kozikowski AP; Shen S; Pardo M; Tavares MT; Szarics D; Benoy V; Zimprich CA; Kutil Z; Zhang G; Bařinka C; Robers MB; Van Den Bosch L; Eubanks JH; Jope RS
ACS Chem Neurosci; 2019 Mar; 10(3):1679-1695. PubMed ID: 30511829
[TBL] [Abstract][Full Text] [Related]
6. Acetylation as a major determinant to microtubule-dependent autophagy: Relevance to Alzheimer's and Parkinson disease pathology.
Esteves AR; Palma AM; Gomes R; Santos D; Silva DF; Cardoso SM
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):2008-2023. PubMed ID: 30572013
[TBL] [Abstract][Full Text] [Related]
7. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic meets metabolism: novel vulnerabilities to fight cancer.
Scumaci D; Zheng Q
Cell Commun Signal; 2023 Sep; 21(1):249. PubMed ID: 37735413
[TBL] [Abstract][Full Text] [Related]
9. Endogenous expression of inactive lysine deacetylases reveals deacetylation-dependent cellular mechanisms.
Toro TB; Skripnikova EV; Bornes KE; Zhang K; Watt TJ
PLoS One; 2023; 18(9):e0291779. PubMed ID: 37721967
[TBL] [Abstract][Full Text] [Related]
10. The Importance of the "Time Factor" for the Evaluation of Inhibition Mechanisms: The Case of Selected HDAC6 Inhibitors.
Cellupica E; Caprini G; Fossati G; Mirdita D; Cordella P; Marchini M; Rocchio I; Sandrone G; Stevenazzi A; Vergani B; Steinkühler C; Vanoni MA
Biology (Basel); 2023 Jul; 12(8):. PubMed ID: 37626935
[TBL] [Abstract][Full Text] [Related]
11. Continuous Fluorescent Sirtuin Activity Assay Based on Fatty Acylated Lysines.
Zessin M; Meleshin M; Hilscher S; Schiene-Fischer C; Barinka C; Jung M; Schutkowski M
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108579
[TBL] [Abstract][Full Text] [Related]
12. Macrocyclic Octapeptide Binding and Inferences on Protein Substrate Binding to Histone Deacetylase 6.
Watson PR; Gupta S; Hosseinzadeh P; Brown BP; Baker D; Christianson DW
ACS Chem Biol; 2023 Apr; 18(4):959-968. PubMed ID: 37027789
[TBL] [Abstract][Full Text] [Related]
13. HDAC6 score: to treat or not to treat?
Hey J; Llamazares Prada M; Plass C
Nat Cancer; 2023 Feb; 4(2):156-158. PubMed ID: 36585451
[No Abstract] [Full Text] [Related]
14. Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.
Cellupica E; Caprini G; Cordella P; Cukier C; Fossati G; Marchini M; Rocchio I; Sandrone G; Vanoni MA; Vergani B; Źrubek K; Stevenazzi A; Steinkühler C
J Biol Chem; 2023 Jan; 299(1):102800. PubMed ID: 36528061
[TBL] [Abstract][Full Text] [Related]
15. HDAC6: A unique HDAC family member as a cancer target.
Kaur S; Rajoria P; Chopra M
Cell Oncol (Dordr); 2022 Oct; 45(5):779-829. PubMed ID: 36036883
[TBL] [Abstract][Full Text] [Related]
16. Accurate Models of Substrate Preferences of Post-Translational Modification Enzymes from a Combination of mRNA Display and Deep Learning.
Vinogradov AA; Chang JS; Onaka H; Goto Y; Suga H
ACS Cent Sci; 2022 Jun; 8(6):814-824. PubMed ID: 35756369
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Therapeutics Targeting NRF2/KEAP1 Signaling in Cancer Oxidative Stress.
Zhang S; Duan S; Xie Z; Bao W; Xu B; Yang W; Zhou L
Front Pharmacol; 2022; 13():924817. PubMed ID: 35754474
[TBL] [Abstract][Full Text] [Related]
18. Structure-based prediction of HDAC6 substrates validated by enzymatic assay reveals determinants of promiscuity and detects new potential substrates.
Varga JK; Diffley K; Welker Leng KR; Fierke CA; Schueler-Furman O
Sci Rep; 2022 Feb; 12(1):1788. PubMed ID: 35110592
[TBL] [Abstract][Full Text] [Related]
19. Hydroxamic acid-modified peptide microarrays for profiling isozyme-selective interactions and inhibition of histone deacetylases.
Moreno-Yruela C; Bæk M; Vrsanova AE; Schulte C; Maric HM; Olsen CA
Nat Commun; 2021 Jan; 12(1):62. PubMed ID: 33397936
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
